Vestal Point Capital Acquires $181.80 Million Stake in Terns Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Source: Fool
Terns Pharmaceuticals Inc. shares rose 3.39% and reached a 52-week high of $46.07 amid positive market conditions.
Vestal Point Capital disclosed a new investment in Terns by acquiring 4.5 million shares worth $181.80 million, reflecting strong confidence in the company's growth prospects, particularly in its lead program for chronic myeloid leukemia. This acquisition positions Terns as 6.7% of Vestal's portfolio, indicating significant market recognition and potential for future growth.
With approximately $1 billion in cash, Terns is well-positioned to fund operations and clinical milestones, enhancing investor confidence and suggesting that the recent stock surge could have lasting momentum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
